A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies

PURPOSE: Anti-KIR monoclonal antibodies (mAbs) can enhance the antitumor responses of natural killer (NK) cells. We evaluated the safety of the anti-KIR2D mAb lirilumab in patients with various cancers. EXPERIMENTAL DESIGN: Thirty-seven patients with hematological malignancies (n = 22) or solid tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Vey, Norbert, Karlin, Lionel, Sadot-Lebouvier, Sophie, Broussais, Florence, Berton-Rigaud, Dominique, Rey, Jérôme, Charbonnier, Aude, Marie, Delphine, André, Pascale, Paturel, Carine, Zerbib, Robert, Bennouna, Jaafar, Salles, Gilles, Gonçalves, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915148/
https://www.ncbi.nlm.nih.gov/pubmed/29707140
http://dx.doi.org/10.18632/oncotarget.24832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915148/
https://www.ncbi.nlm.nih.gov/pubmed/29707140
http://dx.doi.org/10.18632/oncotarget.24832

Ejemplares similares